Anesth Pain Med.  2020 Jul;15(3):291-296. 10.17085/apm.20004.

Effects of tranexamic acid on the activity of glutamate transporter EAAT3

• Shin HJ
• Lee SY
• Na HS
• Koo BW
• Ryu JH
• Do SH

• KMID: 2504890
• DOI: http://doi.org/10.17085/apm.20004

Abstract

Background
Tranexamic acid (TXA) is the most widely used hemostatic agent in surgical patients. However, when used in a high dose, it could cause a seizure in the postoperative period. The exact effector mechanism behind the seizure triggering remains unknown. Therefore, the authors investigated the effects of TXA on the activity of glutamate transporter type 3 (excitatory amino acid transporter 3; EAAT3), which is the main neuronal glutamate transporter type.
Methods
EAAT3 was expressed in Xenopus laevis oocytes through mRNA injection. Oocytes were incubated with diluted tranexamic acid for 72 h. Two-electrode voltage clamping was used to measure membrane currents before, during, and after applying 30 M L-glutamate. Responses were quantified by integrating the current traces and reported in microcoulombs (C). Results were presented as mean  SEM.
Results
TXA (30 to 1,000 M) significantly decreased EAAT3 activity. Our kinetic study showed that Vmax was significantly decreased in the TXA group compared with the control group (1.1  0.1 vs. 1.4  0.1 C, n = 18–23, P = 0.043), but the Km did not significantly change (12.7  3.9 M for TXA vs. 12.8  3.8 for control, n = 18–23, P = 0.986).
Conclusions
Our results suggest that TXA attenuates EAAT3 activity, which may explain its proconvulsant effect.

Keyword

Electrophysiology; Excitatory amino acid transporter 3; Glutamate plasma membrane transport proteins; Tranexamic acid; Xenopus laevis

Figure

• 

  Fig. 1. The EAAT3 expression process. EAAT3: excitatory amino acid transporter 3.

• 

  Fig. 2. Changes in EAAT3 activity relative to tranexamic acid exposure level. EAAT3: excitatory amino acid transporter 3. *P < 0.05 compared with the control group (tranexamic acid concentration 0 μM).

• 

  Fig. 3. EAAT3 dose-response curve of for L-glutamate relative to tranexamic acid presence. EAAT3: excitatory amino acid transporter 3. *P < 0.05 compared with control group (tranexamic acid concentration 0 μM).

Reference

1. Kalavrouziotis D, Voisine P, Mohammadi S, Dionne S, Dagenais F. High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. Ann Thorac Surg. 2012; 93:148–54.

2. Merriman B, Mayson K, Sawka A, Akagami R, Flexman AM. Postoperative seizure in a neurosurgical patient: should tranexamic acid be on the differential? Can J Anaesth. 2013; 60:506–7.

3. Kratzer S, Irl H, Mattusch C, Bürge M, Kurz J, Kochs E, et al. Tranexamic acid impairs γ-aminobutyric acid receptor type A-mediated synaptic transmission in the murine amygdala: a potential mechanism for drug-induced seizures? Anesthesiology. 2014; 120:639–49.

4. Sepkuty JP, Cohen AS, Eccles C, Rafiq A, Behar K, Ganel R, et al. A neuronal glutamate transporter contributes to neurotransmitter GABA synthesis and epilepsy. J Neurosci. 2002; 22:6372–9.

5. Danbolt NC. Glutamate uptake. Prog Neurobiol. 2001; 65:1–105.

6. Beart PM, O'Shea RD. Transporters for L-glutamate: an update on their molecular pharmacology and pathological involvement. Br J Pharmacol. 2007; 150:5–17.

7. Maragakis NJ, Rothstein JD. Glutamate transporters in neurologic disease. Arch Neurol. 2001; 58:365–70.

8. Sheldon AL, Robinson MB. The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int. 2007; 51:333–55.

9. Do SH, Kamatchi GL, Washington JM, Zuo Z. Effects of volatile anesthetics on glutamate transporter, excitatory amino acid transporter type 3: the role of protein kinase C. Anesthesiology. 2002; 96:1492–7.

10. Guo J, Gao X, Ma Y, Lv H, Hu W, Zhang S, et al. Different dose regimes and administration methods of tranexamic acid in cardiac surgery: a meta-analysis of randomized trials. BMC Anesthesiol. 2019; 19:129.

11. Manji RA, Grocott HP, Leake J, Ariano RE, Manji JS, Menkis AH, et al. Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors. Can J Anaesth. 2012; 59:6–13.

12. Zhang Y, Bai Y, Chen M, Zhou Y, Yu X, Zhou H, et al. The safety and efficiency of intravenous administration of tranexamic acid in coronary artery bypass grafting (CABG): a meta-analysis of 28 randomized controlled trials. BMC Anesthesiol. 2019; 19:104.

13. Mathews GC, Diamond JS. Neuronal glutamate uptake contributes to GABA synthesis and inhibitory synaptic strength. J Neurosci. 2003; 23:2040–8.

14. Lecker I, Wang DS, Romaschin AD, Peterson M, Mazer CD, Orser BA. Tranexamic acid concentrations associated with human seizures inhibit glycine receptors. J Clin Invest. 2012; 122:4654–66.

15. Na HS, Park HP, Kim CS, Do SH, Zuo Z, Kim CS. 17β-Estradiol attenuates the activity of the glutamate transporter type 3 expressed in Xenopus oocytes. Eur J Pharmacol. 2012; 676:20–5.

16. Yun JY, Kim JH, Kim HK, Lim YJ, Do SH, Zuo Z. Effects of intravenous anesthetics on the activity of glutamate transporter EAAT3 expressed in Xenopus oocytes: evidence for protein kinase C involvement. Eur J Pharmacol. 2006; 531:133–9.

17. Lecker I, Wang DS, Whissell PD, Avramescu S, Mazer CD, Orser BA. Tranexamic acid-associated seizures: causes and treatment. Ann Neurol. 2016; 79:18–26.

18. Furtmüller R, Schlag MG, Berger M, Hopf R, Huck S, Sieghart W, et al. Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid(A) receptor antagonistic effect. J Pharmacol Exp Ther. 2002; 301:168–73.

19. Kim JH, Do SH, Kim YL, Zuo Z. Effects of chronic exposure to ethanol on glutamate transporter EAAT3 expressed in Xenopus oocytes: evidence for protein kinase C involvement. Alcohol Clin Exp Res. 2005; 29:2046–52.

20. Kim JH, Lim YJ, Ro YJ, Min SW, Kim CS, Do SH, et al. Effects of ethanol on the rat glutamate excitatory amino acid transporter type 3 expressed in Xenopus oocytes: role of protein kinase C and phosphatidylinositol 3-kinase. Alcohol Clin Exp Res. 2003; 27:1548–53.

21. Shin HJ, Ryu JH, Kim ST, Zuo Z, Do SH. Caffeine-induced inhibition of the activity of glutamate transporter type 3 expressed in Xenopus oocytes. Toxicol Lett. 2013; 217:143–8.

22. Yoon HJ, Lim YJ, Zuo Z, Hur W, Do SH. Nicotine decreases the activity of glutamate transporter type 3. Toxicol Lett. 2014; 225:147–52.

23. Ryu J, Do SH, Lee N. Remifentanil increases the activity of the glutamate transporter, EAAC1, expressed in Xenopus oocytes. Anesth Pain Med. 2008; 3:264–9.

24. Ryu JH, Kim CS, Do SH, Park HS. Effect of propofol on oxidative stress-attenuated glutamate transporter EAAT4 activity. Anesth Pain Med. 2011; 6:225–30.